Clinical Trials Logo

Filter by:
NCT ID: NCT04662918 Recruiting - Clinical trials for GastroIntestinal Bleeding

Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

Start date: January 1, 2022
Phase:
Study type: Observational

Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.

NCT ID: NCT04662749 Recruiting - Partial-edentulism Clinical Trials

Influence of Intruding Angle on Non-graft Osteotome Sinus Elevation

Start date: February 16, 2020
Phase:
Study type: Observational

The contour of maxillary sinus matters in osteotome sinus elevation. So does the implant intruding angle between the axis of the implant and the tangent line of the sinus floor contour. The investigators have been engaged in studying the relationship between the outcome of bone formation and the intruding angle, which could guide our clinical decision-making.

NCT ID: NCT04662294 Recruiting - Multiple Myeloma Clinical Trials

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Start date: November 18, 2021
Phase: Early Phase 1
Study type: Interventional

A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases

NCT ID: NCT04662099 Recruiting - Clinical trials for CS1+ or BCMA+ Multiple Myeloma

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

Start date: March 25, 2020
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of the bispecific CAR T cells targeting CS1 and BCMA in patients with relapsed or refractory multiple myeloma.

NCT ID: NCT04661956 Recruiting - Diagnosis Clinical Trials

The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in The Pulmonary Periphral Nodule

Start date: December 15, 2020
Phase: N/A
Study type: Interventional

Transbronchial cryobiopsy under the guidance of endobronchial ultrasound is performed in patients with pulmonary peripheral nodule, and assess the diagnostic yield and safety.

NCT ID: NCT04661943 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

A phase II,single arm,open-label study to assess Maintenance Therapy of Chidamide in Patients With Hepatitis B Virus(HBV)Positive Diffuse Large B-cell Lymphoma with complete response after completion of prior chemotherapy

NCT ID: NCT04661449 Recruiting - Clinical trials for Childhood Overweight

Effects of Lifestyle Intervention on Childhood Outcomes in LGA Infants

Start date: January 22, 2021
Phase: N/A
Study type: Interventional

Large-for-gestational-age (LGA) infants have a higher risk of metabolic disease later in life, and their postnatal growth in early childhood may be associated with long-term adverse outcomes. The purpose of this study is to explore whether comprehensive lifestyle intervention in the first year after birth in LGA infants will reduce the rate of overweight/obesity at childhood and improve neurodevelopmental outcomes and its possible mechanism.

NCT ID: NCT04661020 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Start date: December 3, 2020
Phase: Phase 2
Study type: Interventional

A Study of CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma.

NCT ID: NCT04660565 Recruiting - Clinical trials for IgG4-related Disease

Belimumab Treatment for IgG4-related Disease

Start date: January 2021
Phase: Phase 4
Study type: Interventional

Even though glucocorticoid is the current first line medication for IgG4-RD, it is well accepted in the field that excessive dosage of GC, especially accumulative dosage, is associated with increasing organ damage. Although B cell depletion with rituximab has been verified to be an effective treatment for IgG4-RD, even without concomitant GC therapy, rituximab can increase the risk of infection during the treatment. Belimumab is an IgG1-lambda monoclonal antibody that prevents the survival of B lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to receptors on B lymphocytes. Previous studies and trails suggested that the activity of B-cell mediated immunity and autoimmune responses were ameliorated after belimumab without increasing rates of adverse events when compared to standard of care . However, the efficacy and tolerability of belimumab in IgG4-RD patients have not been examined before. This randomized, control clinical trial aimed to evaluate the tolerability and the efficacy of Belimumab for maintenance treatment for IgG4-RD.

NCT ID: NCT04660487 Recruiting - Clinical trials for Graft Versus Host Disease

Relationship Between "FODMAPs" and "GVHD"

Start date: December 1, 2020
Phase:
Study type: Observational

With the stem cell transplanting increasing, patients which effected with "GVHD" were also increased. To evaluation the relationship between "FODMAPs" and "GVHD", Bone marrow transplant patients were recruited.